Knowledge Accumulation And Industry Evolution


Download Knowledge Accumulation And Industry Evolution PDF/ePub or read online books in Mobi eBooks. Click Download or Read Online button to get Knowledge Accumulation And Industry Evolution book now. This website allows unlimited access to, at the time of writing, more than 1.5 million titles, including hundreds of thousands of titles in various foreign languages.

Download

Knowledge Accumulation and Industry Evolution


Knowledge Accumulation and Industry Evolution

Author: Mariana Mazzucato

language: en

Publisher: Cambridge University Press

Release Date: 2006-03-09


DOWNLOAD





This book explores how the biotechnology and pharmaceutical sector is affected by innovation, growth and public policy.

Knowledge Generation and Protection


Knowledge Generation and Protection

Author: Jorge Mario Martínez-Piva

language: en

Publisher: Springer Science & Business Media

Release Date: 2009-12-03


DOWNLOAD





This book is the English version of the text published by the Economic Commission for Latin America and the Caribbean in April 2008 and entitled Generación y protección del conocimiento: propiedad intelectual, innovación y desarrollo 1 económico. Since then, the year that has passed has been fraught with uncertainty but has also brought signs of hope. Indeed, the past year was marked by the outbreak of the deepest and most p- vasive nancial and economic crisis since the Great Depression of 1929, a crisis generated in the United States but whose negative repercussions have spread at a phenomenal rate throughout the planet. The impact of this crisis on the p- ples of Latin America and the Caribbean will undermine the region’s prospects for economic growth, employment, and poverty alleviation. This was the year in which United States citizens elected Barack Obama as their President, a clear sign of new hope. This hope was tangible at the Fifth Summit of the Americas, held in 2009 in Port of Spain, which marked a turning point in the relations between the countries that make up this hemisphere. The open posture of the United States and that country’s readiness to listen rather than to impose any particular position and its willingness to engage in dialogue on an equal footing were positive signs. Moreover, it was generally admitted that there is not just one model for advancing successfully toward development.

Access to Non-Summary Clinical Trial Data for Research Purposes Under EU Law


Access to Non-Summary Clinical Trial Data for Research Purposes Under EU Law

Author: Daria Kim

language: en

Publisher: Springer Nature

Release Date: 2021-10-19


DOWNLOAD





This book draws a unique perspective on the regulation of access to clinical trial data as a case on research and knowledge externalities. Notwithstanding numerous potential benefits for medical research and public health, many jurisdictions have struggled to ensure access to clinical trial data, even at the level of the trial results. Pro-access policy initiatives have been strongly opposed by research-based drug companies arguing that mandatory data disclosure impedes their innovation incentives. Conventionally, access to test data has been approached from the perspective of transparency and research ethics. The book offers a complementary view and considers access to individual patient-level trial data for exploratory analysis as a matter of research and innovation policy. Such approach appears to be especially relevant in the data-driven economy where digital data constitutes a valuable economic resource. The study seeks to define how the rules of access to clinical trial data should be designed to reconcile the policy objectives of leveraging the research potential of data through secondary analysis, on the one hand, and protecting economic incentives of research-based drug companies, on the other hand. Overall, it is argued that the mainstream innovation-based justification for exclusive control over the outcomes of research and development can hardly rationalise trial sponsors’ control over primary data from trials. Instead, access to such data and its robust analysis should be prioritised.